Blue Jet Healthcare Ltd, one of India’s leading manufacturers of contrast media intermediates used in medical imaging, today broke ground for a Rs 2,300-crore greenfield pharmaceutical manufacturing facility at Rambilli Industrial Park in Anakapalli district.

Spread across over 102 acres near Visakhapatnam, the project will create new production capacities for contrast media intermediates, high-intensity sweeteners and multipurpose chemistry units.

As per the details obtained from the state government the facility will be developed in phases and is targeted to become operational by FY2028–29.

Speaking on the occasion AP’s IT minister Mr Nara Lokesh reiterated the state government’s strong emphasis on speed of doing business, trust and credibility.

We have brand Chandrababu Naidu who enjoys credibility globally, said Mr Lokesh.

The Rambilli project entails an investment of approximately Rs 2,300 crore and is expected to generate 1,750 direct jobs and 250 indirect jobs, significantly strengthening the industrial profile of the Visakhapatnam economic region.

Importantly, the facility will integrate an advanced Effluent Treatment Plant (ETP) with marine discharge connectivity and incorporate Zero Liquid Discharge (ZLD) technologies.

According to the company profile, this system is designed to enable a 70% reduction in energy consumption while recovering 90–95% of wastewater   — a critical factor as global pharma supply chains tighten ESG and compliance benchmarks.

The investment is expected to deepen India’s domestic manufacturing base in high-value specialty intermediates at a time when global pharmaceutical companies are increasingly diversifying supply chains beyond single geographies.

About Blue Jet Healthcare

Founded in 1968 as Jet Chemicals Private Limited, Blue Jet Healthcare has evolved into a science-led specialty pharmaceutical and healthcare ingredients company headquartered in Maharashtra.

Today, it operates as an integrated Contract Development and Manufacturing Organisation (CDMO), supplying advanced pharmaceutical intermediates, APIs, contrast media intermediates and high-intensity sweeteners to customers across India, Europe, the United States and other international markets.

The company is recognised as one of India’s leading players in contrast media intermediates and an early pioneer of saccharin manufacturing in the country.

The company is led by Executive Chairman Mr Akshay Bansarilal Arora and its Managing Director Mr Shiven Akshay Arora.

Andhra’s Pharma Ambitions

For Andhra Pradesh, the groundbreaking signals further momentum in its cluster-based industrial push, particularly in pharmaceuticals and bulk drugs.

The Rambilli Industrial Park is being positioned as a hub for high-value chemical and pharma manufacturing along the eastern coast.